These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15150554)

  • 1. Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
    Humphreys AC; Dent J; Rodwell S; Crawford SM; Joffe JK; Bradley C; Dodwell D; Perren TJ
    Br J Cancer; 2004 Jun; 90(11):2131-4. PubMed ID: 15150554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
    Waters SH; Gillibrand A; Berry H; Kumar S; Velikova G; Dodwell DJ; Perren TJ
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):407-12. PubMed ID: 19455333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
    Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R
    Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
    Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
    Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
    Nieto Y; Aramendía JM; Espinós J; De la Cruz S; Fernández-Hidalgo O; Santisteban M; Arbea L; Aristu J; Martínez-Monge R; Moreno M; Pina L; Sola J; Zornoza G; Regueira FM
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):457-65. PubMed ID: 19526361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
    Salminen E; Korpela J; Varpula M; Asola R; Varjo P; Pyrhönen S; Mali P; Hinkka S; Ekholm E
    Anticancer Drugs; 2002 Oct; 13(9):925-9. PubMed ID: 12394255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
    Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
    Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
    Lortholary A; Maillard P; Delva R; Boisdron-Celle M; Perard D; Vernillet L; Besenval M; Gamelin E
    Eur J Cancer; 2000 Sep; 36(14):1773-80. PubMed ID: 10974625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
    Holmes FA; Hellerstedt BA; Pippen JE; Vukelja SJ; Collea RP; Kocs DM; Blum JL; McIntyre KJ; Barve MA; Brooks BD; Osborne CR; Wang Y; Asmar L; O'Shaughnessy J
    Cancer Med; 2018 Jun; 7(6):2288-2298. PubMed ID: 29582557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
    Mavroudis D; Papakotoulas P; Ardavanis A; Syrigos K; Kakolyris S; Ziras N; Kouroussis C; Malamos N; Polyzos A; Christophyllakis C; Kentepozidis N; Georgoulias V;
    Ann Oncol; 2010 Jan; 21(1):48-54. PubMed ID: 19906761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
    Hénin E; Meille C; Barbolosi D; You B; Guitton J; Iliadis A; Freyer G
    Breast Cancer Res Treat; 2016 Apr; 156(2):331-41. PubMed ID: 27002506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
    Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
    Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
    Nuzzo F; Morabito A; Gravina A; Di Rella F; Landi G; Pacilio C; Labonia V; Rossi E; De Maio E; Piccirillo MC; D'Aiuto G; Thomas R; Rinaldo M; Botti G; Di Bonito M; Di Maio M; Gallo C; Perrone F; de Matteis A
    BMC Cancer; 2011 Feb; 11():75. PubMed ID: 21324184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
    Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A
    Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.